Search

Your search keyword '"Hosoda, Mitsuchika"' showing total 164 results
Start Over Author "Hosoda, Mitsuchika"
164 results on '"Hosoda, Mitsuchika"'

2. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition

Author

Terada, Mitsuo, Ito, Aki, Kikawa, Yuichiro, Koizumi, Kei, Naito, Yoichi, Shimoi, Tatsunori, Ishihara, Mikiya, Yamanaka, Takashi, Ozaki, Yukinori, Hara, Fumikata, Nakamura, Rikiya, Hattori, Masaya, Miyashita, Minoru, Kondo, Naoto, Yoshinami, Tetsuhiro, Takada, Masahiro, Matsumoto, Koji, Narui, Kazukata, Sasada, Shinsuke, Iwamoto, Takayuki, Hosoda, Mitsuchika, Takano, Yuko, Oba, Takaaki, Sakai, Hitomi, Murakami, Akari, Higuchi, Toru, Tsuchida, Junko, Tanabe, Yuko, Shigechi, Tomoko, Tokuda, Emi, Harao, Michiko, Kashiwagi, Shinichiro, Mase, Junichi, Watanabe, Junichiro, Nagai, Shigenori E., Yamauchi, Chikako, Yamamoto, Yutaka, Iwata, Hiroji, Saji, Shigehira, and Toyama, Tatsuya

Published
2023
Full Text
View/download PDF

3. A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study).

Author

Kikawa, Yuichiro, primary, Uemura, Yukari, additional, Taira, Tetsuhiko, additional, Kitagawa, Chiyoe, additional, Maeda, Hideki, additional, Kato, Hiroaki, additional, Hashimoto, Naoki, additional, Hosoda, Mitsuchika, additional, Hamanaka, Yohei, additional, Tanabe, Yuko, additional, Yoshida, Tatsuya, additional, Tane, Kaori, additional, Takabatake, Daisuke, additional, Ishikawa, Takashi, additional, Iwamoto, Takayuki, additional, Yamaguchi, Takeshi, additional, Takiguchi, Daisuke, additional, Mukai, Hirofumi, additional, Taira, Naruto, additional, and Sangai, Takafumi, additional

Published
2024
Full Text
View/download PDF

6. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Author

Ogiya, Akiko, Yamazaki, Kieko, Horii, Rie, Shien, Tadahiko, Horimoto, Yoshiya, Masuda, Norikazu, Inao, Touko, Hosoda, Mitsuchika, Ishida, Naoko, Osako, Tomofumi, Takahashi, Masato, Endo, Yumi, Miyoshi, Yuichiro, Yasojima, Hiroyuki, Tomioka, Nobumoto, Yamashita, Hiroko, and Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Published
2017
Full Text
View/download PDF

7. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer

Author

Yamashita, Hiroko, Ogiya, Akiko, Shien, Tadahiko, Horimoto, Yoshiya, Masuda, Norikazu, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, Endo, Yumi, Hosoda, Mitsuchika, Ishida, Naoko, Horii, Rie, Yamazaki, Kieko, Miyoshi, Yuichiro, Yasojima, Hiroyuki, Tomioka, Nobumoto, and Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Published
2016
Full Text
View/download PDF

12. Abstract OT1-12-08: Randomized study comparing electronic patient reported outcomes (ePROs) monitoring with routine follow up during trastuzumab deruxtecan treatment in patients with inoperable or metastatic breast cancer (PRO-DUCE study)

Author

Sangai, Takafumi, primary, Kikawa, Yuichiro, additional, Hosoda, Mitsuchika, additional, Hamanaka, Yohei, additional, Tanabe, Yuko, additional, Yoshida, Tatsuya, additional, Tane, Kaori, additional, Takabatake, Daisuke, additional, Taira, Tetsuhiko, additional, Araki, Kazuhiro, additional, Iwamoto, Takayuki, additional, Takada, Mamoru, additional, Narui, Kazutaka, additional, Yamaguchi, Takeshi, additional, Yamada, Akimitsu, additional, Miura, Tomoko, additional, Uemura, Yukari, additional, Aihara, Tomohiko, additional, Mukai, Hirofumi, additional, and Taira, Naruto, additional

Published
2022
Full Text
View/download PDF

15. Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Author

Ogiya, Akiko, Yamazaki, Kieko, Horii, Rie, Shien, Tadahiko, Horimoto, Yoshiya, Masuda, Norikazu, Inao, Touko, Hosoda, Mitsuchika, Ishida, Naoko, Osako, Tomofumi, Takahashi, Masato, Endo, Yumi, Miyoshi, Yuichiro, Yasojima, Hiroyuki, Tomioka, Nobumoto, Yamashita, Hiroko, and Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Published
2017
Full Text
View/download PDF

29. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor‑positive/human epidermal growth factor receptor type 2 negative breast cancer

Author

Miyoshi, Yuichiro, primary, Shien, Tadahiko, additional, Ogiya, Akiko, additional, Ishida, Naoko, additional, Yamazaki, Kieko, additional, Horii, Rie, additional, Horimoto, Yoshiya, additional, Masuda, Norikazu, additional, Yasojima, Hiroyuki, additional, Inao, Touko, additional, Osako, Tomofumi, additional, Takahashi, Masato, additional, Tomioka, Nobumoto, additional, Wanifuchi‑Endo, Yumi, additional, Hosoda, Mitsuchika, additional, Doihara, Hiroyoshi, additional, and Yamashita, Hiroko, additional

Published
2018
Full Text
View/download PDF

30. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer.

Author

Miyoshi, Yuichiro, Shien, Tadahiko, Ogiya, Akiko, Ishida, Naoko, Yamazaki, Kieko, Horii, Rie, Horimoto, Yoshiya, Masuda, Norikazu, Yasojima, Hiroyuki, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, Tomioka, Nobumoto, Wanifuchi-Endo, Yumi, Hosoda, Mitsuchika, Doihara, Hiroyoshi, and Yamashita, Hiroko

Subjects
HORMONE receptor positive breast cancer, EPIDERMAL growth factor receptors, BREAST cancer, HORMONE therapy, TUMOR grading, PROGESTERONE receptors
Abstract

The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years following the primary operation, 134 with late distant recurrence diagnosed following 5 years or longer and 321 controls without recurrence for >10 years following starting the initial treatment for ER-positive/HER2 negative breast cancer, registered in 9 institutions, were analyzed. The distributions of TILs and their clinical relevance were investigated. TIL distributions did not differ significantly among the early, late and no recurrence groups, employing a 30% cut-off point as a dichotomous variable. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064). The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group). High TIL distributions also predicted shorter survival time following the detection of recurrence (P=0.026). However, these prognostic interactions were not significant in multivariate analysis (P=0.200). The present retrospective study demonstrated no significant interaction between TIL proportions and the timing of recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes, which tended to be more responsive to chemotherapy. The clinical relevance of stromal TILs for identifying patients who would likely benefit from additional therapies merits further investigation in a larger patient population. [ABSTRACT FROM AUTHOR]

Published
2019

31. Differences in morphological features and minimum apparent diffusion coefficient values among breast cancer subtypes using 3-tesla MRI

Author

Kato, Fumi, Kudo, Kohsuke, Yamashita, Hiroko, Wang, Jeff, Hosoda, Mitsuchika, Hatanaka, Kanako C., Mimura, Rie, Oyama-Manabe, Noriko, Shirato, Hiroki, Kato, Fumi, Kudo, Kohsuke, Yamashita, Hiroko, Wang, Jeff, Hosoda, Mitsuchika, Hatanaka, Kanako C., Mimura, Rie, Oyama-Manabe, Noriko, and Shirato, Hiroki

Abstract

Purpose: To compare the morphology and minimum apparent diffusion coefficient (ADC) values among breast cancer subtypes. Methods: Ninety-three patients, who underwent breast MRI and collectively had 98 pathologically proven invasive carcinomas, were enrolled. Morphology was evaluated according to BIRADS-MRI. Minimum ADC was measured. Morphology and minimum ADC were compared among subtypes. Multivariate logistic regression analyses were used to identify the characteristics associated with different subtypes. Results: Oval/round shape was significantly associated with triple-negative (TN) cancer (TN vs. non-TN: 90.9% vs. 45.2%; p = 0.0123). Rim enhancement was significantly less frequent in Luminal A (Luminal A vs. non-Luminal A: 34.2% vs. 76.1%; p = 0.0003). The minimum ADC of Luminal A was significantly higher than that of Luminal B (HER2-negative) (834 vs. 748 x 10^-6 mm2/s; p <0.025). The minimum ADC of the TN-special type was significantly higher than that of TN-ductal (997 vs. 702 x 10^-6 mm2/s; p <0.025). On the multivariate analysis comparing the characteristics associated with Luminal A vs. Luminal B (HER2-negative), the internal enhancement characteristics of the mass and minimum ADC were significant factors. Conclusion: Morphology and minimum ADC would be useful in distinguishing breast cancer subtypes.

Published
2016

32. Differences in morphological features and minimum apparent diffusion coefficient values among breast cancer subtypes using 3-tesla MRI

Author

1000080399865, Kato, Fumi, 1000010374232, Kudo, Kohsuke, 1000070332947, Yamashita, Hiroko, Wang, Jeff, 1000040443931, Hosoda, Mitsuchika, Hatanaka, Kanako C., Mimura, Rie, 1000070463742, Oyama-Manabe, Noriko, 1000020187537, Shirato, Hiroki, 1000080399865, Kato, Fumi, 1000010374232, Kudo, Kohsuke, 1000070332947, Yamashita, Hiroko, Wang, Jeff, 1000040443931, Hosoda, Mitsuchika, Hatanaka, Kanako C., Mimura, Rie, 1000070463742, Oyama-Manabe, Noriko, 1000020187537, and Shirato, Hiroki

Abstract

Purpose: To compare the morphology and minimum apparent diffusion coefficient (ADC) values among breast cancer subtypes. Methods: Ninety-three patients, who underwent breast MRI and collectively had 98 pathologically proven invasive carcinomas, were enrolled. Morphology was evaluated according to BIRADS-MRI. Minimum ADC was measured. Morphology and minimum ADC were compared among subtypes. Multivariate logistic regression analyses were used to identify the characteristics associated with different subtypes. Results: Oval/round shape was significantly associated with triple-negative (TN) cancer (TN vs. non-TN: 90.9% vs. 45.2%; p = 0.0123). Rim enhancement was significantly less frequent in Luminal A (Luminal A vs. non-Luminal A: 34.2% vs. 76.1%; p = 0.0003). The minimum ADC of Luminal A was significantly higher than that of Luminal B (HER2-negative) (834 vs. 748 x 10^-6 mm2/s; p <0.025). The minimum ADC of the TN-special type was significantly higher than that of TN-ductal (997 vs. 702 x 10^-6 mm2/s; p <0.025). On the multivariate analysis comparing the characteristics associated with Luminal A vs. Luminal B (HER2-negative), the internal enhancement characteristics of the mass and minimum ADC were significant factors. Conclusion: Morphology and minimum ADC would be useful in distinguishing breast cancer subtypes.

Published
2016

33. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer

Author

1000070332947, Yamashita, Hiroko, Ogiya, Akiko, 1000030509451, Shien, Tadahiko, Horimoto, Yoshiya, Masuda, Norikazu, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, 1000020566228, Endo, Yumi, 1000040443931, Hosoda, Mitsuchika, Ishida, Naoko, 1000020446272, Horii, Rie, Yamazaki, Kieko, Miyoshi, Yuichiro, Yasojima, Hiroyuki, Tomioka, Nobumoto, Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society, 1000070332947, Yamashita, Hiroko, Ogiya, Akiko, 1000030509451, Shien, Tadahiko, Horimoto, Yoshiya, Masuda, Norikazu, Inao, Touko, Osako, Tomofumi, Takahashi, Masato, 1000020566228, Endo, Yumi, 1000040443931, Hosoda, Mitsuchika, Ishida, Naoko, 1000020446272, Horii, Rie, Yamazaki, Kieko, Miyoshi, Yuichiro, Yasojima, Hiroyuki, Tomioka, Nobumoto, and Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Abstract

Background: Most studies analyzing prognostic factors for late relapse have been performed in postmenopausal women who received tamoxifen or aromatase inhibitors as adjuvant endocrine therapy for estrogen receptor (ER)-positive breast cancer. Methods: A total of 223 patients (108 premenopausal and 115 postmenopausal) with early distant recurrence and 149 patients (62 premenopausal and 87 postmenopausal) with late distant recurrence of ER-positive, HER2-negative breast cancer who were given their initial treatment between 2000 and 2004 were registered from nine institutions. For each late recurrence patient, approximately two matched control patients without relapse for more than ten years were selected. Clinicopathological factors and adjuvant therapies were compared among the three groups by menopausal status and age. Results: Factors predicting early recurrence in premenopausal women were large tumor size, high lymph node category and high tumor grade, whereas predictors for late recurrence were large tumor size and high lymph node category. In postmenopausal women under 60 years of age, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, low PgR expression and high Ki67 labeling index (LI), while predictors for late recurrence were large tumor size and high lymph node category. On the other hand, in postmenopausal women aged 60 years or older, factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, high tumor grade, low ER expression and high Ki67 LI, whereas predictors for late recurrence were high lymph node category, low ER expression and short duration of adjuvant endocrine therapy. Conclusion: Predictors of early and late distant recurrence might differ according to menopausal status and age.

Published
2016

37. Fulvestrant 500 mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience

Author

Ishida, Naoko, primary, Araki, Kazuhiro, additional, Sakai, Takehiko, additional, Kobayashi, Kokoro, additional, Kobayashi, Takayuki, additional, Fukada, Ippei, additional, Hosoda, Mitsuchika, additional, Yamamoto, Mitsugu, additional, Ichinokawa, Kazuomi, additional, Takahashi, Shunji, additional, Iwase, Takuji, additional, Ito, Yoshinori, additional, and Yamashita, Hiroko, additional

Published
2015
Full Text
View/download PDF

39. A Case of Myeloid Sarcoma of the Breast

Author

KASHIWAKURA, Sayuri, primary, YAMAMOTO, Mitsugu, additional, HOSODA, Mitsuchika, additional, MITSUHASHI, Tomoko, additional, TAKETOMI, Akinobu, additional, and YAMASHITA, Hiroko, additional

Published
2015
Full Text
View/download PDF

40. Co-Overexpression of GEP100 and AMAP1 Proteins Correlates with Rapid Local Recurrence after Breast Conservative Therapy

Author

Kinoshita, Rumiko, Nam, Jin-Min, Ito, Yoichi M., Hatanaka, Kanako C., 1000060390803, Hashimoto, Ari, Handa, Haruka, Otsuka, Yutaro, 1000050311303, Hashimoto, Shigeru, 1000090435561, Onodera, Yasuhito, 1000040443931, Hosoda, Mitsuchika, Onodera, Shunsuke, 1000050463724, Shimizu, Shinichi, 1000070261287, Tanaka, Shinya, 1000020187537, Shirato, Hiroki, 1000090360908, Tanino, Mishie, 1000040187282, Sabe, Hisataka, Kinoshita, Rumiko, Nam, Jin-Min, Ito, Yoichi M., Hatanaka, Kanako C., 1000060390803, Hashimoto, Ari, Handa, Haruka, Otsuka, Yutaro, 1000050311303, Hashimoto, Shigeru, 1000090435561, Onodera, Yasuhito, 1000040443931, Hosoda, Mitsuchika, Onodera, Shunsuke, 1000050463724, Shimizu, Shinichi, 1000070261287, Tanaka, Shinya, 1000020187537, Shirato, Hiroki, 1000090360908, Tanino, Mishie, 1000040187282, and Sabe, Hisataka

Abstract

A major problem of current cancer research and therapy is prediction of tumor recurrence after initial treatment, rather than the simple biological characterization of the malignancy and proliferative properties of tumors. Breast conservation therapy (BCT) is a well-approved, standard treatment for patients with early stages of breast cancer, which consists of lumpectomy and whole-breast irradiation. In spite of extensive studies, only 'age' and 'Ki-67 positivity' have been identified to be well correlated with local recurrence after BCT. An Arf6 pathway, activated by GEP100 under receptor tyrosine kinases (RTKs) and employs AMAP1 as its effector, is crucial for invasion and metastasis of some breast cancer cells. This pathway activates beta 1 integrins and perturbs E-cadherin-based adhesions, hence appears to be integral for epithelial-mesenchymal transdifferentiation (EMT). We here show that expression of the Arf6 pathway components statistically correlates with rapid local recurrence after BCT. We retrospectively analyzed four hundred seventy-nine patients who received BCT in Hokkaido University Hospital, and found 20 patients had local recurrence. We then analyzed pathological samples of patients who experienced local recurrence by use of Kaplan-Meier analysis, Stepwise regression analysis and the t-test, coupled with immunostaining, and found that co-overexpression of GEP100 and AMAP1 correlates with rapidity of the local recurrence. Their margin-status, node-positivity, and estrogen receptor (ER)-or progesterone receptor (PgR)positivity did not correlated with the rapidity. This study is the first to show that expression of a certain set of proteins correlates with the rapidity of local recurrence. Our results are useful not only for prediction, but highlight the possibility of developing novel strategies to block local recurrence. We also discuss why mRNAs encoding these proteins have not been identified to correlate with local recurrence by previous conventi

Published
2013

43. Co-Overexpression of GEP100 and AMAP1 Proteins Correlates with Rapid Local Recurrence after Breast Conservative Therapy

Author

Kinoshita, Rumiko, primary, Nam, Jin-Min, additional, Ito, Yoichi M., additional, Hatanaka, Kanako C., additional, Hashimoto, Ari, additional, Handa, Haruka, additional, Otsuka, Yutaro, additional, Hashimoto, Shigeru, additional, Onodera, Yasuhito, additional, Hosoda, Mitsuchika, additional, Onodera, Shunsuke, additional, Shimizu, Shinichi, additional, Tanaka, Shinya, additional, Shirato, Hiroki, additional, Tanino, Mishie, additional, and Sabe, Hisataka, additional

Published
2013
Full Text
View/download PDF

44. Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01).

Author

Yamamoto, Naohito, primary, Yamashiro, Hiroyasu, additional, Iwata, Hiroji, additional, Masuda, Norikazu, additional, Ohtani, Shoichiro, additional, Takahashi, Masato, additional, Yamazaki, Kosuke, additional, Kato, Makoto, additional, Ohno, Shinji, additional, Kuroi, Katsumasa, additional, Yamagami, Kazuhiko, additional, Morimoto, Takashi, additional, Hasegawa, Yoshie, additional, Takano, Toshimi, additional, Kadoya, Takayuki, additional, Hosoda, Mitsuchika, additional, Abe, Hajime, additional, Morita, Satoshi, additional, Yasuno, Shinji, additional, and Toi, Masakazu, additional

Published
2013
Full Text
View/download PDF

45. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 36-month results.

Author

Takahashi, Shunji, primary, Iwase, Takuji, additional, Kohno, Norio, additional, Ishikawa, Takashi, additional, Kim, Seung Jin, additional, Hosoda, Mitsuchika, additional, Horiguchi, Jun, additional, Yamauchi, Hideko, additional, Hozumi, Yasuo, additional, Okada, Morihito, additional, Fukunaga, Masao, additional, and Noguchi, Shinzaburo, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results